Off-Label Considerations?
This article was originally published in The Gray Sheet
Executive Summary
One detail in the draft guidance that may catch the attention of some in industry is in the section on technology, engineering and performance changes.
You may also be interested in...
Institute Of Medicine On 510(k) Review Program: Dump It
The Institute of Medicine committee charged with reviewing FDA's 510(k) device pre-market review program is urging the agency to ditch the 35-year-old program and start fresh.
Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: